Financial Personal
ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology
Engineering antibodies in silico using LENSaiā¢ marks a significant milestone toward the complete de novo design of antibodies, aligning with IPA’s vision to make groundbreaking and safer therapeutics instantly accessible and affordable. Key tak
Engineering antibodies in silico using LENSaiā¢ marks a significant milestone toward the complete de novo design of antibodies, aligning with IPA's vision to make groundbreaking and safer therapeutics instantly accessible and affordable. Read More
